ViroVet is a Belgian company developing livestock solutions for controlling viral diseases in livestock. Its primary focus is creating antiviral drugs and vaccines that target respiratory disease complexes and viral infections in swine.
Virovet’s pipeline includes 1.) Plasmid Launched Live Attenuated Virus (PLLAV) vaccines, which use a unique technology platform to offer tailor-made solutions for maximum efficacy and safety while eliminating the need for a cold chain, and 2.) fast-acting antiviral drugs to combat respiratory diseases like African Swine Fever (ASF) and to reduce secondary infections associated with the use of antibiotics like Bovine Viral Diarrhea (BVD).
Funding and financials
Virovet’s latest funding round was in May 2020, when it raised EUR 6 million (~USD 6.6 million) in Series B funding led by Seventure Partners, with participation from PMV, Biotech Fund Flanders, Capricorn Partners, Agri Investment Fund, KU Leuven, Gemma Frisius Fund, and Vives II.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.